Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Liu S, Breitbart A, Sun Y, Mehta PD, Boutajangout A, Scholtzova H, Wisniewski T.

J Neurochem. 2014 Feb;128(4):577-91. doi: 10.1111/jnc.12484. Epub 2013 Nov 6.

2.

A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T.

Am J Pathol. 2004 Sep;165(3):937-48.

3.

Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice.

Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T.

J Alzheimers Dis. 2011;24(2):269-85. doi: 10.3233/JAD-2011-101401.

4.

Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T.

Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18787-92. Epub 2006 Nov 20.

5.

Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.

Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM.

J Neurosci. 2014 May 21;34(21):7281-92. doi: 10.1523/JNEUROSCI.0646-14.2014.

6.

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.

Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ.

Acta Neuropathol Commun. 2014 Jun 28;2:75. doi: 10.1186/s40478-014-0075-0.

7.

Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.

Oddo S, Caccamo A, Cheng D, LaFerla FM.

Brain Pathol. 2009 Jul;19(3):421-30. doi: 10.1111/j.1750-3639.2008.00194.x. Epub 2008 Jul 24.

8.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674
9.

Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice.

Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2012 Sep 19;32(38):13125-36.

10.

Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.

Goñi F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta P, Wisniewski T.

J Neuroinflammation. 2013 Dec 13;10:150. doi: 10.1186/1742-2094-10-150.

11.

Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.

Scholtzova H, Chianchiano P, Pan J, Sun Y, Goñi F, Mehta PD, Wisniewski T.

Acta Neuropathol Commun. 2014 Sep 2;2:101. doi: 10.1186/s40478-014-0101-2.

12.

Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM.

J Neurosci. 2005 Mar 16;25(11):2803-10.

13.

Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.

Van Dooren T, Muyllaert D, Borghgraef P, Cresens A, Devijver H, Van der Auwera I, Wera S, Dewachter I, Van Leuven F.

Am J Pathol. 2006 Jan;168(1):245-60.

14.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

15.

Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline.

Liu S, Park S, Allington G, Prelli F, Sun Y, Martá-Ariza M, Scholtzova H, Biswas G, Brown B, Verghese PB, Mehta PD, Kwon YU, Wisniewski T.

Sci Rep. 2017 Aug 14;7(1):8009. doi: 10.1038/s41598-017-08604-8.

16.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

17.

Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.

Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, Méndez E, Jiménez-Huete A, Beavis R, Gallo G, Gomez-Tortosa E, Ghiso J, Hyman BT, Frangione B, Ghetti B.

Acta Neuropathol. 2000 Jul;100(1):1-12.

PMID:
10912914
18.

Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.

Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG.

J Neurochem. 2013 Aug;126(4):473-82. doi: 10.1111/jnc.12305. Epub 2013 Jun 16.

19.

Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T.

BMC Neurosci. 2010 Oct 14;11:130. doi: 10.1186/1471-2202-11-130.

20.

Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Guzmán EA, Bouter Y, Richard BC, Lannfelt L, Ingelsson M, Paetau A, Verkkoniemi-Ahola A, Wirths O, Bayer TA.

Mol Neurodegener. 2014 Apr 2;9:13. doi: 10.1186/1750-1326-9-13.

Supplemental Content

Support Center